A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions

Inclusion Criteria: * Subjects are female * Subjects are 18 years of age or older at the time of consent * Subjects have a BMI between 17-40 * Subjects must have signed informed consent form * Subjects have a preoperative diagnosis of uterine fibroids and plan to have a myomectomy completed surgically as part of their standard of care * Subjects must have a physical examination and compliance assessment Exclusion Criteria: * Subjects whose BMI is outside the range of 17-40 * Subjects participating in another clinical trial with a drug or device * Subjects who have participated in a clinical trial with a drug or device within 30 days prior to this study * Subjects with suspected or diagnosed pregnancy * Subjects with suspected intraabdominal infection * Subjects who are immunocompromised * Subjects diagnosed with cancer * Subjects treated with hemostatic agents (e.g. fibrin sealant, collagen, oxidized cellulose) * Subjects treated with adhesion prevention agents other than the Anti-Adhesion product (APP) (e.g. Intergel ® Adhesion Prevention Solution, Seprafilm ® Membrane) * Subjects taking anti-epileptic medication * Subjects who have been treated with Methotrexate or other chemotherapeutics agents * Subjects with an American Fertility Society score of Stage D at the time of myomectomy as determined by the surgeon * Positive viral serology screening results for hepatitis B surface antigen, antibodies to hepatitis C virus or human immunodeficiency